🇺🇸 FDA
Patent

US 7855202

Imidazopyridine derivatives as A2B adenosine receptor antagonists

granted A61PA61P1/00A61P11/00

Quick answer

US patent 7855202 (Imidazopyridine derivatives as A2B adenosine receptor antagonists) held by Laboratories Almirall, S.A. expires Mon Dec 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Laboratories Almirall, S.A.
Grant date
Tue Dec 21 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P1/00, A61P11/00, A61P11/06, A61P11/08